Joseph P. McEvoy, MD

Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta University, Augusta, Georgia

JCP
Original Research

March 23, 2021

Insomnia is common in schizophrenia, but how does it affect suicidality and symptoms in these patients? This analysis of CATIE data provides answers.
Brian J. Miller, Joseph P. McEvoy, William V. McCall
JCP
Webcast

March 9, 2021

In brief videos, Drs McEvoy and Nierenberg discuss symptoms of tardive dyskinesia, how to observe patients (whether in person or via telemedicine), and how to educate patients and families...
Joseph P. McEvoy, Andrew A. Nierenberg
JCP
DELETE eReport

November 3, 2020

Measurement-based care (MBC) has been found to be effective in patients with psychiatric conditions. In this CME activity, learn how Dr Joseph McEvoy employs MBC for patients with tardive...
Joseph P. McEvoy
JCP
DELETE eReport

September 29, 2020

Read an article on how to reduce Tardive dyskinesia (TD) symptoms, including the use of the FDA-approved treatment options (valbenazine and deutetrabenazine).
Joseph P. McEvoy
JCP
Academic Highlights

January 28, 2020

Review highlights from 2 experts' presentations on identifying and treating tardive dyskinesia. Quotes from actual patients illustrate the embarrassment that they feel and show why even mild movements should...
Joseph P. McEvoy, Daniel E. Kremens
JCP
Consensus Statement

January 28, 2020

Tardive dyskinesia remains a serious complication associated with dopamine receptor blocking agents. In this article, read guidance from experts on best practices for tardive dyskinesia screening, diagnosis, and treatment.
Stanley N. Caroff, Leslie Citrome, Jonathan Meyer, et al
JCP
Educational Activity

December 17, 2019

Two medications are FDA-approved to treat tardive dyskinesia, and new long-term evidence has been reported. Follow along as expert Joseph P. McEvoy, MD, reviews the evidence.
Joseph P. McEvoy
JCP
Educational Activity

December 3, 2019

How does tardive dyskinesia affect patients' work and relationships? Should TD be treated even if patients lack insight into its presence? Dr Joseph McEvoy considers these questions and more...
Joseph P. McEvoy
JCP
Original Research

December 18, 2018

Could valbenazine help your patients who experience antipsychotic-induced abnormal movements? This follow-up analysis of a phase 3 study provides further insights into the efficacy of valbenazine for tardive dyskinesia...
Christoph U. Correll, Andrew J. Cutler, John M. Kane, et al
JCP
Original Research

November 27, 2018

Which subgroups of patients with schizophrenia or schizoaffective disorder may be prone to treatment failure? Is it men or women, old or young, or are more factors involved? Researchers...
T. Scott Stroup, Natalie A. Bareis, Robert A. Rosenheck, et al
JCP
Educational Activity

February 21, 2018

Do you know how to manage tardive dyskinesia symptoms? In this Case and Comment activity, consider the case of John, a 25-year-old project manager diagnosed with bipolar disorder who...
Joseph P. McEvoy
JCP
Educational Activity

February 21, 2018

Do you know which of your patients are at risk for developing tardive dyskinesia? Watch this Webcast to learn about how to prevent tardive dyskinesia in your patients and...
J. Sloan Manning, Joseph P. McEvoy

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe